Latest News

Liza O’Dowd, MD, Discusses What Sets Icotrokinra Apart in Psoriasis Treatment Following NDA Submission
Liza O’Dowd, MD, Discusses What Sets Icotrokinra Apart in Psoriasis Treatment Following NDA Submission

July 31st 2025

O'Dowd discusses J&J's recent NDA submission for icotrokinra in psoriasis.

Sun Pharma Announces Positive Phase 3 Results for Tildrakizumab in Psoriatic Arthritis
Sun Pharma Announces Positive Phase 3 Results for Tildrakizumab in Psoriatic Arthritis

July 22nd 2025

Beyond Efficacy: Why We Need a New Look at Drug Safety
Beyond Efficacy: Why We Need a New Look at Drug Safety

July 22nd 2025

Johnson & Johnson Submits NDA for Icotrokinra in Plaque Psoriasis
Johnson & Johnson Submits NDA for Icotrokinra in Plaque Psoriasis

July 21st 2025

Apremilast Shows Promise in Genital Psoriasis
Apremilast Shows Promise in Genital Psoriasis

July 21st 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.